Strata Critical Medical, Inc. (SRTA)
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
- Symbol
- SRTA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $462.11M
- 52 week range
- 3.95 - 6.5
Valuation
- Share price
- $5.38 (close of 2026-09-23)
- P/E (TTM)
- 10.72x
- Price to book
- 1.65x
- Price to free cash flow
- -9.54x
- Enterprise value
- $450.04M
- Book value per share
- $3.24
Price performance
| Period | Change |
|---|
| 1 day | -0.37% |
| 5 days | +1.70% |
| 1 month | -13.78% |
| 3 months | -3.41% |
| 6 months | +24.25% |
| Year to date | +11.85% |
| 1 year | -3.24% |
| 3 years | +101.50% |
| 5 years | -52.56% |
| All time | -44.82% |
Profitability and growth
- Return on equity
- 14.82%
- Return on invested capital
- -8.89%
- Return on assets
- 12.70%
- Return on capital employed
- -7.31%
- Gross margin
- 20.86%
- Net margin
- 20.97%
- EBITDA margin
- -7.19%
- Revenue growth
- 34.28%
- Net income growth
- 251.42%
- Free cash flow growth
- -75.28%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -10.48%
- Current ratio
- 2.64x
- Net debt to EBITDA
- 2.93x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $197.14M
- Cost of revenue
- $156.01M
- Gross profit
- $41.13M
- EBITDA
- $-14.17M
- Net income
- $41.35M
- Earnings per share
- $0.50
- Shares outstanding
- 82.09M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $197.14M | $41.13M | $41.35M | $0.50 |
| 2024-12-31 | $146.82M | $29.59M | $-27.31M | $-0.35 |
| 2023-12-31 | $225.18M | $42.12M | $-56.08M | $-0.76 |
| 2022-12-31 | $146.12M | $22.27M | $-27.26M | $-0.38 |
| 2021-09-30 | $50.53M | $10.52M | $-40.05M | $-0.93 |
| 2020-12-31 | - | - | $-20.52M | $-2.17 |
| 2020-09-30 | $23.43M | $2.33M | $-10.16M | $-0.40 |
| 2019-12-31 | - | - | $2.33M | $0.19 |
| 2019-09-30 | $31.20M | $4.70M | $-10.84M | $-0.43 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 20.86% | 20.97% | 14.82% | -8.89% |
| 2024-12-31 | 20.15% | -18.60% | -12.30% | -10.90% |
| 2023-12-31 | 18.71% | -24.90% | -23.93% | -28.86% |
| 2022-12-31 | 15.24% | -18.66% | -9.93% | -20.98% |
| 2021-09-30 | 20.82% | -79.27% | -13.75% | -7.18% |
| 2020-12-31 | - | - | -410.44% | -16.33% |
| 2020-09-30 | 9.93% | -43.36% | -91.70% | - |
| 2019-12-31 | - | - | 46.63% | - |
| 2019-09-30 | 15.06% | -34.74% | -52.27% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $30.97M |
| 2024-12-31 | $18.38M |
| 2023-12-31 | $27.87M |
| 2022-12-31 | $41.34M |
| 2021-09-30 | $6.95M |
| 2020-12-31 | $846.07K |
| 2020-09-30 | $12.16M |
| 2019-12-31 | $1.31M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-58.51M | $17.83M |
| 2024-12-31 | $-33.38M | $19.89M |
| 2023-12-31 | $-34.46M | $12.50M |
| 2022-12-31 | $-37.86M | $8.28M |
| 2021-09-30 | $-15.91M | $9.62M |
| 2020-12-31 | $-794.47K | - |
| 2020-09-30 | $-11.20M | $490.00K |
| 2019-09-30 | $-10.91M | $317.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
- Consensus EPS estimate
- $0.01
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-04 | Jun/2026 | - |
| 2026-05-06 | - | - |
| 2026-03-03 | - | - |
| 2025-11-10 | - | - |
| 2025-08-05 | - | - |
| 2025-05-12 | - | - |
| 2025-03-13 | - | - |
| 2024-11-12 | - | - |
Filings and sources
- Company website
- stratacritical.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades